Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2101-2120 of 3,900 trials

Colorectal Cancer: FAPI-PET Imaging Study

We are investigating whether FAPI-PET imaging can help detect tumor-associated fibrosis in patients with colorectal peritoneal metastases. This may improve diagnosis and treatment planning.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)GastroenterologyOncology

Relapsing Multiple Sclerosis: CYB704 vs. Ocrevus

We are comparing a new biosimilar treatment to Ocrevus for people with relapsing multiple sclerosis. The study aims to evaluate how well it works and its safety profile.

Multiple Sclerosis Relapse>2 yearsConfirmation phase (III)Neurology

Elderly Primary CNS Lymphoma: High-Dose Chemotherapy Study

We are comparing a high-dose chemotherapy followed by stem cell transplantation to standard chemotherapy for elderly patients with primary CNS lymphoma. The goal is to see which treatment leads to better survival and quality of life.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Viral Infections After Stem Cell Transplant: Multispecific T-Cell Therapy

We are studying a new treatment using multispecific T-cells for patients with viral infections that resist chemotherapy after stem cell transplantation. The goal is to see if this therapy can improve symptoms and overall health.

Viral Infections After Stem Cell Transplant>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesHematologyInfectious DiseasesOncology

LPH-5: First-in-Man Safety Study

We are investigating a new drug called LPH-5 in healthy volunteers to see how safe it is and how it works in the body. This study will help us understand its effects compared to a placebo.

Depression6-12 monthsSafety phase (I)Psychiatry

Amantadine for Improving Alertness in ICU Patients

We are studying whether Amantadine can enhance responsiveness in patients receiving intensive care. The trial will measure changes in alertness over several days using established clinical scoring systems.

Unresponsive Wakefulness Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Prostate Cancer: New Radioactive Treatment Study

We are testing a new radioactive drug for adults with metastatic castration-resistant prostate cancer who have not had chemotherapy. The study will assess the safety and how well the treatment works in these patients.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Standard MedicinesOncology

RCS-21: Safety Study in Healthy Volunteers

We are testing the safety and tolerability of the compound RCS-21 in healthy individuals. This study will help us understand how the body absorbs and eliminates this drug.

Healthy Participants1-2 yearsSafety phase (I)Pulmonology

Solid Tumors: MCLA-128 Treatment Study

We are studying a new bispecific antibody, MCLA-128, in patients with solid tumors that have an NRG1 fusion. The goal is to evaluate its safety and how well it may work against these tumors.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Chemotherapy and Immunotherapy for Pancoast Tumor in Lung Cancer

We are studying the effects of chemotherapy and immunotherapy before and after surgery in patients with non-small cell lung cancer located in the upper part of the lungs. The goal is to see if this approach improves survival and treatment outcomes.

Pancoast's TumorEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Breast Cancer: Trastuzumab Deruxtecan vs. CDK4/6 Inhibitors

We are studying whether trastuzumab deruxtecan is more effective than a combination of CDK4/6 inhibitors and endocrine therapy for patients with HR-positive, HER2-low advanced breast cancer. This research aims to improve treatment options for this specific group of patients.

Locally Recurrent or Metastatic Hormone Receptor-Positive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOncology

Small-Cell Lung Cancer: Durvalumab and Olaparib Maintenance Therapy

We are studying the effects of a combination of durvalumab and olaparib for patients with HRD-positive extensive disease small-cell lung cancer after initial treatment. The goal is to see if this maintenance therapy improves outcomes and is safe for patients.

Extensive Stage Small Cell Lung Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Advanced Solid Tumors: STP938 Treatment Study

We are testing a new drug called STP938 in adults with advanced solid tumors, including those with a specific type of ovarian cancer. The study aims to evaluate the safety of this treatment.

Ovarian CancerSolid Tumors>2 yearsSafety phase (I)Oncology

PRT7732 for Advanced Solid Tumors with SMARCA4 Mutation

We are testing a new oral medication for patients with advanced or metastatic solid tumors that have a specific genetic mutation. The goal is to see if it can help improve treatment outcomes.

Esophageal, Gastric, or Gastroesophageal Junction AdenocarcinomaEsophageal, Gastric, or Gastroesophageal Junction Squamous Cell CarcinomaNon-Small Cell Lung Cancer (NSCLC)>2 yearsSafety phase (I)Oncology

Migraine Prevention in Kids: Rimegepant Study

We are testing a new medication, rimegepant, to see if it helps reduce migraine days in children and adolescents aged 6 to under 18. The study compares its effects to a placebo to understand its potential benefits.

Migraine≤3 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Duchenne Muscular Dystrophy: Satralizumab Study

We are studying the effects of satralizumab in children and teens with Duchenne muscular dystrophy. This trial aims to see if it is safe and how it impacts bone health and metabolism.

Duchenne Muscular Dystrophy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyNeurologyPediatrics

Anesthesia in Young Children: Low-Dose vs. Standard Sevoflurane

We are comparing the effects of low-dose sevoflurane combined with dexmedetomidine and remifentanil against standard sevoflurane anesthesia on cognitive development in children under 2 years old. The goal is to see which method supports better brain development as they grow.

General Anesthesia in Young Children>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Cardiac Surgery: Fibrinogen Concentrate Study

We are testing a new treatment to manage bleeding in patients undergoing complex cardiac surgery. The goal is to see if it reduces the need for blood transfusions compared to a placebo.

Functional Disturbances After Cardiac SurgeryBleeding in Cardiac Surgery Patients>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Tumor Treatment: ABX-001 Immunotherapy

We are testing a new immunotherapy, ABX-001, alone and with pembrolizumab for patients with tumors that have been treated before. The goal is to see if this combination can improve treatment outcomes.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Hemolytic Uremic Syndrome: INM004 Treatment for Kids

We are studying a new treatment for children with Hemolytic Uremic Syndrome caused by E. coli to see if it helps improve kidney function and reduce complications. The trial will also evaluate the safety of this treatment.

Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesNephrologyPediatrics